GSK banks on promis­ing da­ta from its PhI­II Gem­i­ni pro­gram to stare down Gilead on HIV — but there are plen­ty of skep­tics

Af­ter more than a decade’s worth of work, Glax­o­SmithK­line $GSK re­searchers to­day are un­veil­ing pooled da­ta from their two late-stage tri­als of a two-drug reg­i­men for keep­ing HIV in check. Fac­ing off against some deep-seat­ed skep­ti­cism and a pow­er­house ri­val at Gilead $GILD, the phar­ma gi­ant’s ma­jor­i­ty owned sub­sidiary Vi­iV says the com­bo per­formed just as well as a triplet in their big face­off in­volv­ing treat­ment-naive pa­tients, mak­ing it a like­ly new en­try in the glob­al fight against the virus that spurs AIDS.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER